Acute-on-chronic liver failure (ACLF) is a fatal disease that develops in the basis of chronic liver diseases due to acute precipitating events. The lack of definite therapies for ACLF other than liver transplantation urges us to investigate its pathophysiological mechanism. It has been recognized that systemic inflammation is a major driver of ACLF. Although the link between systemic inflammation and organ failure has been established, less is known about how systemic inflammation forms and how it impacts on the organ functions. On the other hand, immunosuppression is another facet of immune derangement of ACLF, which leads to secondary bacterial infections and worsens the situation. However, so far, we know very little on the development of immunosuppression during ACLF and its molecular mechanisms. Thus, this disease is still a big challenge to both clinicians and researchers.
The immune derangement of ACLF is characterized by systemic inflammation and immunosuppression. Therefore, one aspect of this Research Topics is to define the concept of systemic inflammation in the context of ACLF. We should clarify the anatomy of systemic inflammation, including the inducers (DAMP and PAMP), immune cells, cytokines and other elements, and their specific roles. We should also investigate how systemic inflammation impacts on organ function and thereby precipitates the development of organ failure. The other aspect of this Research Topic is to delineate immunosuppression in ACLF. Likewise, we need to define immunosuppression by elucidating its causative mechanisms and uncover the specific stage of ACLF at which immunosuppression occurs. Besides, it is essential to further evaluate the impact of immunosuppression on the progression of ACLF. The investigation at these two facets of immune derangement of ACLF will lead to the discovery of biomarkers and potential therapeutical targets. We welcome manuscripts from, but not limited to, the following subtopics:
• Characterization of the dynamics of immune status of ACLF patients and investigation on its association with precipitants, the underlying chronic liver diseases, clinical course, and complications
• Identification of novel immune cell subsets, cytokines, inducers, and their regulatory network that contribute to the development of systemic inflammation or immunosuppression in ACLF
• Association between systemic inflammation/immunosuppression and dysbiosis in ACLF
• Molecular mechanisms underlying systemic inflammation-induced organ failure
• The impact of immunosuppression on the risk of complications and outcomes of ACLF
• Translational studies developing novel immuno-biomarker-guiding models to accurately predict the outcome of ACLF
Acute-on-chronic liver failure (ACLF) is a fatal disease that develops in the basis of chronic liver diseases due to acute precipitating events. The lack of definite therapies for ACLF other than liver transplantation urges us to investigate its pathophysiological mechanism. It has been recognized that systemic inflammation is a major driver of ACLF. Although the link between systemic inflammation and organ failure has been established, less is known about how systemic inflammation forms and how it impacts on the organ functions. On the other hand, immunosuppression is another facet of immune derangement of ACLF, which leads to secondary bacterial infections and worsens the situation. However, so far, we know very little on the development of immunosuppression during ACLF and its molecular mechanisms. Thus, this disease is still a big challenge to both clinicians and researchers.
The immune derangement of ACLF is characterized by systemic inflammation and immunosuppression. Therefore, one aspect of this Research Topics is to define the concept of systemic inflammation in the context of ACLF. We should clarify the anatomy of systemic inflammation, including the inducers (DAMP and PAMP), immune cells, cytokines and other elements, and their specific roles. We should also investigate how systemic inflammation impacts on organ function and thereby precipitates the development of organ failure. The other aspect of this Research Topic is to delineate immunosuppression in ACLF. Likewise, we need to define immunosuppression by elucidating its causative mechanisms and uncover the specific stage of ACLF at which immunosuppression occurs. Besides, it is essential to further evaluate the impact of immunosuppression on the progression of ACLF. The investigation at these two facets of immune derangement of ACLF will lead to the discovery of biomarkers and potential therapeutical targets. We welcome manuscripts from, but not limited to, the following subtopics:
• Characterization of the dynamics of immune status of ACLF patients and investigation on its association with precipitants, the underlying chronic liver diseases, clinical course, and complications
• Identification of novel immune cell subsets, cytokines, inducers, and their regulatory network that contribute to the development of systemic inflammation or immunosuppression in ACLF
• Association between systemic inflammation/immunosuppression and dysbiosis in ACLF
• Molecular mechanisms underlying systemic inflammation-induced organ failure
• The impact of immunosuppression on the risk of complications and outcomes of ACLF
• Translational studies developing novel immuno-biomarker-guiding models to accurately predict the outcome of ACLF
